[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cognitive-deficit-in-attention\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cognitive-deficit-in-attention":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,73],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100563357","the-effect-of-different-types-of-focus-instructions-in-parkinsons-rehabilitation-100563357",false,"NCT06615115","The Effect of Different Types of Focus Instructions in Parkinson's Rehabilitation","Effects of an External and Combined Focus of Attention-Instructed Exercise Program on Postural Stability and Dual-Task Walking in Parkinson's Disease: A Randomized, Assessor-Blinded, Controlled Trial","Inclusion Criteria:\n\n* Hoehn and Yahr Stage II or III\n* Individuals between the ages of 50 and 70 who can walk independently but have balance disorders\n* Having a score between 21-56 on the Berg Balance Scale\n* Having a score between 24-30 on the Mini Mental State Test\n* Having agreed to participate in the study (Not having a freezing phenomenon)\n* Being in the Medication-on period\n\nExclusion Criteria:\n\n* Having malignancy and metabolic diseases\n* Having had Cerebrovascular Accident before\n* Other neurological disease history\n* Presence of cognitive problems\n* Presence of visual or hearing disorders\n* Presence of deep brain pacemaker\n* Presence of freezing phenomenon (persons with Freezing of Gait Questionnaire FOG-Q above zero)\n* Presence of dyskinesia",true,"ALL","50 Years","70 Years",{"count":21,"type":22},48,"ESTIMATED","INTERVENTIONAL",[25],"NA","Parkinson's disease is the most common progressive neurodegenerative movement disorder. Common movement impairments in Parkinson's include balance and walking difficulties. These impairments lead to falls, increased levels of functional dependency, and a decrease in quality of life. Exercise in Parkinson's patients improves their functional symptoms in daily life, enhancing both motor and non-motor skills, and consequently increases their quality of life. Recently, various additional methods have been developed to increase the effectiveness of exercise in Parkinson's rehabilitation and to contribute to motor skills. Focus of attention instructions are fundamental concepts in motor function learning. External focus of attention has been shown to facilitate motor function development, reduce postural instability, and improve dual-task walking by being easier to remember. In Parkinson's patients who experience freezing phenomena, internal focus of attention instructions enhance walking stability and movement control, thereby reducing the risk of falls. However, there are no studies on the combined focus of attention instructions in Parkinson's patients. This study is designed as a randomized controlled, single-blind, prospective trial to examine the effects of a combination of internal and external focus of attention instructions on walking, balance parameters, quality of life, and patient satisfaction levels, taking into account the presence of freezing phenomena in Parkinson's patients.",[28,29,30,31],"Parkinson Disease","Cognitive Deficit in Attention","Feedback, Psychological","Gait, Festinating","RECRUITING","2025-02-10",{"date":35,"type":36},"2025-02-11","ACTUAL",{"date":38,"type":36},"2025-01-30",{"date":40,"type":22},"2025-12-30",{"name":42,"class":43},"Bahçeşehir University","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":44},"100479896","feasibilityacceptability-of-attentional-control-training-in-survivors-100479896","NCT05528939","Feasibility\u002FAcceptability of Attentional-Control Training in Survivors","FAACTS: Feasibility\u002FAcceptability of Attentional-Control Training in Survivors","FAACTS","Inclusion Criteria:\n\n* Aged 8-16 years at time of screening.\n* History of diagnosis of acute lymphoblastic leukemia (ALL) or brain tumor (BT).\n* At least 1 year from completion of planned therapy and stable from a disease standpoint.\n* Participating child and caregiver are fluent in spoken English.\n* Availability of a caregiver who is willing and capable of providing support and supervision during cognitive training.\n* Participating child is either not taking any prescribed stimulant medication for attention difficulties or has been prescribed a stable dose of stimulant medication for attention difficulties for at least 30 days prior to enrollment.\n* Only patients with a T-score ≥ 75th percentile on the CPT-3 Omission Errors scale or on the BRIEF-2 Cognitive Regulation Index will be randomized.\n\nExclusion Criteria:\n\n* A history of photosensitive seizures.\n* A motor, visual, or auditory handicap that prevents computer use.\n* A mental health condition that precludes, or takes treatment precedence over, participation in the cognitive training.\n* Participants identified during the baseline assessment as having a full-scale IQ \\\u003C 80, as estimated by WASI-II (Vocabulary and Matrix Reasoning), will not be randomized.","8 Years","16 Years",{"count":56,"type":22},50,[25],"This is a multicenter pilot randomized controlled trial, with an active control condition, of the feasibility, acceptability, and preliminary efficacy of EndeavorRx in a cohort of survivors of acute lymphoblastic leukemia or brain tumor ages 8-16 who are \\> 1 year from the end of therapy.",[60,61,62,63,29],"Pediatric Cancer","Pediatric ALL","Pediatric Brain Tumor","Attention Difficulties","2025-01-08",{"date":66,"type":36},"2025-01-10",{"date":68,"type":36},"2023-06-14",{"date":70,"type":22},"2025-08-31",{"name":72,"class":43},"Children's National Research Institute",{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":54,"enrollmentInfo":80,"targetDuration":4,"studyType":23,"phases":82,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":87,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":44},"100446933","feasibility-and-efficacy-of-attentional-control-training-in-sickle-cell-disease-100446933","NCT05099874","Feasibility and Efficacy of Attentional-Control Training in Sickle Cell Disease","ACT","Inclusion Criteria:\n\n* diagnosis of SCD\n* ages 8-16 years\n* maintained on monthly blood transfusions consistently for at least 3 months.\n* patients will be proceed to the intervention phase only if they have a T-score \\> 75th percentile for Omission Errors on the Conners' Continuous Performance Test, 3rd Edition (CPT-3) or a T-score \\> 75th percentile for the Inattention subscale of the ADHD Rating Scale, Fifth Edition (ADHD-RS-V).\n\nExclusion Criteria:\n\n* estimated Intelligence Quotient \\\u003C 70\n* motor, visual, or auditory impairment that prevents computer use\n* known diagnosis of a mental health condition that precludes, or takes treatment precedence over, participation in cognitive training\n* history of photosensitive seizures\n* insufficient English fluency.",{"count":81,"type":22},20,[25],"Children with sickle cell disease (SCD) exhibit significantly reduced cognitive functioning (often difficulties with attention) compared to peers and siblings without SCD. EndeavorRx (Akili Interactive Labs: Boston, MA) is an FDA-approved home-based, electronic attentional-control training program designed to treat attention problems in youth. Users access EndeavorRx on a tablet device for 25-30 minutes each day, 5 days per week, for 4 weeks. The program involves training in a game-like environment that repeatedly challenges attentional-control abilities and adapts to user performance, becoming more difficult over time as performance improves. This pilot study is examining the feasibility, acceptability, and preliminary efficacy of EndeavorRx in a sample of 20 children with SCD ages 8-16 who are being treated with chronic blood transfusion therapy.",[85,86,29],"Sickle Cell Disease","Attention Deficit",{"date":66,"type":36},{"date":89,"type":36},"2022-12-20",{"date":91,"type":22},"2025-12",{"name":72,"class":43}]